Fig. 2

Mutant p53 MSCs-derived tumor lines display enhanced metabolism. a Glucose uptake was evaluated by 2-NBDG incubation (50 µM, for 30 minutes) by Imaging Flow Cytometry (IFC). b Localization levels of GLUT1 protein at the plasma membrane was evaluated by Imaging Flow Cytometry (IFC). c In vitro basal lactate secretion. d, e GC-MS measurements of cell extracts from p53Mut-pMSCs and p53Mut-MSC-TLs incubated for 7 h with RPMI containing 10 mM of uniformly labeled ¹³C-Glucose (d) or 4 mM of uniformly labeled ¹³C-Glutamine (e). Percentage of ¹³C enrichment for Citrate as % [(M + 2) + (M + 4) isotopologues] in (D) and % M + 4 isotopologue in (e). f GC-MS measurements of tumor extracts derived from p53Mut-pMSCs and p53Mut-MSC-TLs subcutaneously injected. Once established, tumors were isolated and incubated for 9 h with DMEM containing 10 mM of uniformly labeled ¹³C-Glucose. Percentage of ¹³C enrichment for lactate as % M + 3. A minimum of three mice per cohort was used. g GC-MS measurements of tumor extracts derived from p53Mut-pMSCs and p53Mut-MSC-TLs subcutaneously injected. Once established, tumors were isolated and incubated for 9 h with DMEM containing 4 mM of uniformly labeled ¹³C-Glutamine. Percentage of ¹³C enrichment for Citrate as % M + 4. A minimum of three mice per cohort was used. Data are presented as mean ± SD, except for mean ± SEM in (a, b) of three independent experiments. *p < 0.05, **p < 0.01. Paired Student’s t test